101
|
Bhattacharjya S, Straus SK. Design, Engineering and Discovery of Novel α-Helical and β-Boomerang Antimicrobial Peptides against Drug Resistant Bacteria. Int J Mol Sci 2020; 21:ijms21165773. [PMID: 32796755 PMCID: PMC7460851 DOI: 10.3390/ijms21165773] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Revised: 08/06/2020] [Accepted: 08/07/2020] [Indexed: 12/18/2022] Open
Abstract
In an era where the pipeline of new antibiotic development is drying up, the continuous rise of multi-drug resistant (MDR) and extensively drug resistant (XDR) bacteria are genuine threats to human health. Although antimicrobial peptides (AMPs) may serve as promising leads against drug resistant bacteria, only a few AMPs are in advanced clinical trials. The limitations of AMPs, namely their low in vivo activity, toxicity, and poor bioavailability, need to be addressed. Here, we review engineering of frog derived short α-helical AMPs (aurein, temporins) and lipopolysaccharide (LPS) binding designed β-boomerang AMPs for further development. The discovery of novel cell selective AMPs from the human proprotein convertase furin is also discussed.
Collapse
Affiliation(s)
- Surajit Bhattacharjya
- School of Biological Sciences, 60 Nanyang Drive, Nanyang Technological University, Singapore 637551, Singapore
- Correspondence: (S.B.); (S.K.S.)
| | - Suzana K. Straus
- Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada
- Correspondence: (S.B.); (S.K.S.)
| |
Collapse
|
102
|
Knauer S, Koch N, Uth C, Meusinger R, Avrutina O, Kolmar H. Sustainable Peptide Synthesis Enabled by a Transient Protecting Group. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.202003676] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Sascha Knauer
- Sulfotools GmbH In der Niederwiesen 24a 64291 Darmstadt Germany
- Institute for Organic Chemistry and Biochemistry TU Darmstadt Alarich-Weiss-Strasse 4 64287 Darmstadt Germany
| | - Niklas Koch
- Sulfotools GmbH In der Niederwiesen 24a 64291 Darmstadt Germany
| | - Christina Uth
- Sulfotools GmbH In der Niederwiesen 24a 64291 Darmstadt Germany
| | - Reinhard Meusinger
- Institute for Organic Chemistry and Biochemistry TU Darmstadt Alarich-Weiss-Strasse 4 64287 Darmstadt Germany
| | - Olga Avrutina
- Institute for Organic Chemistry and Biochemistry TU Darmstadt Alarich-Weiss-Strasse 4 64287 Darmstadt Germany
| | - Harald Kolmar
- Institute for Organic Chemistry and Biochemistry TU Darmstadt Alarich-Weiss-Strasse 4 64287 Darmstadt Germany
| |
Collapse
|
103
|
Yang SH, Clemett CA, Brimble MA, O'Carroll SJ, Harris PWR. Synthesis and biological evaluation of S-lipidated lipopeptides of a connexin 43 channel inhibitory peptide. RSC Med Chem 2020; 11:1041-1047. [PMID: 33479696 DOI: 10.1039/d0md00172d] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Accepted: 06/18/2020] [Indexed: 01/08/2023] Open
Abstract
The synthesis and biological activity of 42 novel S-lipidated analogues of a connexin 43 channel inhibitory Peptide5 is described. Unmodified Peptide5 moderates hemichannels and gap junctions that are both implicated in the progression of neurological disease. Peptide5 was site-specifically modified with a cysteine residue, which then underwent thiol-ene mediated S-lipidation to afford S-lipidated Peptide5 analogues containing straight-chain, branched, or aromatic lipids. The modified peptides were assessed for their effect on hemichannel opening and the most promising candidates were evaluated in serum stability studies.
Collapse
Affiliation(s)
- Sung-Hyun Yang
- School of Chemical Sciences , The University of Auckland , 23 Symonds St , Auckland , New Zealand . .,School of Biological Sciences , The University of Auckland , 3a Symonds St, Private Bag 92019 , Auckland , New Zealand
| | - Connor A Clemett
- Department of Anatomy Medical Imaging , School of Medical Sciences , Faculty of Medical and Health Sciences, and Centre for Brain Research , University of Auckland , Private Bag 92019 , Auckland , New Zealand .
| | - Margaret A Brimble
- School of Chemical Sciences , The University of Auckland , 23 Symonds St , Auckland , New Zealand . .,School of Biological Sciences , The University of Auckland , 3a Symonds St, Private Bag 92019 , Auckland , New Zealand.,Maurice Wilkins Centre for Molecular Biodiscovery , The University of Auckland , 3a Symonds St , Auckland , New Zealand
| | - Simon J O'Carroll
- Department of Anatomy Medical Imaging , School of Medical Sciences , Faculty of Medical and Health Sciences, and Centre for Brain Research , University of Auckland , Private Bag 92019 , Auckland , New Zealand .
| | - Paul W R Harris
- School of Chemical Sciences , The University of Auckland , 23 Symonds St , Auckland , New Zealand . .,School of Biological Sciences , The University of Auckland , 3a Symonds St, Private Bag 92019 , Auckland , New Zealand.,Maurice Wilkins Centre for Molecular Biodiscovery , The University of Auckland , 3a Symonds St , Auckland , New Zealand
| |
Collapse
|
104
|
Karwal P, Vats ID, Sinha N, Singhal A, Sehgal T, Kumari P. Therapeutic Applications of Peptides against Zika Virus: A Review. Curr Med Chem 2020; 27:3906-3923. [DOI: 10.2174/0929867326666190111115132] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2018] [Revised: 11/22/2018] [Accepted: 12/28/2018] [Indexed: 01/27/2023]
Abstract
Zika Virus (ZIKV) belongs to the class of flavivirus that can be transmitted by Aedes
mosquitoes. The number of Zika virus caused cases of acute infections, neurological disorders and
congenital microcephaly are rapidly growing and therefore, in 2016, the World Health Organization
declared a global “Public Health Emergency of International Concern”. Anti-ZIKV therapeutic and
vaccine development strategies are growing worldwide in recent years, however, no specific and safe
treatment is available till date to save the human life. Currently, development of peptide therapeutics
against ZIKV has attracted rising attention on account of their high safety concern and low development
cost, in comparison to small therapeutic molecules and antibody-based anti-viral drugs. In present
review, an overview of ZIKV inhibition by peptide-based inhibitors including E-protein derived
peptides, antimicrobial peptides, frog skin peptides and probiotic peptides has been discussed. Peptides
inhibitors have also been reported to act against NS5, NS2B-NS3 protease and proteasome in
order to inhibit ZIKV infection. Recent advances in peptide-based therapeutics and vaccine have
been reviewed and their future promise against ZIKV infections has been explored.
Collapse
Affiliation(s)
- Preeti Karwal
- Department of Biochemistry, Deshbandhu College, University of Delhi, Delhi-110019, India
| | - Ishwar Dutt Vats
- Department of Chemistry, Deshbandhu College, University of Delhi, Delhi-110019, India
| | - Niharika Sinha
- Drug Development Laboratory Group, Gautam Buddha University, Noida, India
| | - Anchal Singhal
- Department of Chemistry, St. Joseph's College, Bengaluru, Karnataka, India
| | - Teena Sehgal
- Department of Chemistry, HMRITM, GGSIP University, New Delhi, India
| | - Pratibha Kumari
- Department of Chemistry, Deshbandhu College, University of Delhi, Delhi-110019, India
| |
Collapse
|
105
|
Muramatsu W, Hattori T, Yamamoto H. Game Change from Reagent- to Substrate-Controlled Peptide Synthesis. BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN 2020. [DOI: 10.1246/bcsj.20200057] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Wataru Muramatsu
- Molecular Catalyst Research Center, Chubu University, 1200 Matsumoto-cho, Kasugai, Aichi 487-8501, Japan
| | - Tomohiro Hattori
- Molecular Catalyst Research Center, Chubu University, 1200 Matsumoto-cho, Kasugai, Aichi 487-8501, Japan
| | - Hisashi Yamamoto
- Molecular Catalyst Research Center, Chubu University, 1200 Matsumoto-cho, Kasugai, Aichi 487-8501, Japan
| |
Collapse
|
106
|
Maurya NS, Kushwaha S, Mani A. Recent Advances and Computational Approaches in Peptide Drug Discovery. Curr Pharm Des 2020; 25:3358-3366. [PMID: 31544714 DOI: 10.2174/1381612825666190911161106] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Accepted: 09/05/2019] [Indexed: 12/19/2022]
Abstract
BACKGROUND Drug design and development is a vast field that requires huge investment along with a long duration for providing approval to suitable drug candidates. With the advancement in the field of genomics, the information about druggable targets is being updated at a fast rate which is helpful in finding a cure for various diseases. METHODS There are certain biochemicals as well as physiological advantages of using peptide-based therapeutics. Additionally, the limitations of peptide-based drugs can be overcome by modulating the properties of peptide molecules through various biomolecular engineering techniques. Recent advances in computational approaches have been helpful in studying the effect of peptide drugs on the biomolecular targets. Receptor - ligand-based molecular docking studies have made it easy to screen compatible inhibitors against a target.Furthermore, there are simulation tools available to evaluate stability of complexes at the molecular level. Machine learning methods have added a new edge by enabling accurate prediction of therapeutic peptides. RESULTS Peptide-based drugs are expected to take over many popular drugs in the near future due to their biosafety, lower off-target binding chances and multifunctional properties. CONCLUSION This article summarises the latest developments in the field of peptide-based therapeutics related to their usage, tools, and databases.
Collapse
Affiliation(s)
- Neha S Maurya
- Department of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad, India
| | - Sandeep Kushwaha
- Department of Plant Breeding, Sveriges lantbruksuniversitet, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | - Ashutosh Mani
- Department of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad, India
| |
Collapse
|
107
|
Walsh SJ, Iegre J, Seki H, Bargh JD, Sore HF, Parker JS, Carroll JS, Spring DR. General dual functionalisation of biomacromolecules via a cysteine bridging strategy. Org Biomol Chem 2020; 18:4224-4230. [PMID: 32432632 DOI: 10.1039/d0ob00907e] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Site-selective modification of peptides and proteins has resulted in the development of a host of novel tools for the study of cellular systems or the synthesis of enhanced biotherapeutics. There is a need for useful methodologies that enable site-selective modification of native peptides or proteins, which is even more prevalent when modification of the biomolecule with multiple payloads is desired. Herein, we report the development of a novel dual functional divinylpyrimidine (dfDVP) platform that enables robust and modular modification of peptides, antibody fragments and antibodies. These biomacromolecules could be easily functionalised with a range of functional payloads (e.g. fluorescent dyes, cytotoxic warheads or cell-penetrating tags). Importantly, the dual functionalised peptides and antibodies demonstrated exquisite bioactivity in a range of in vitro cellular assays, showcasing the enhanced utility of these bioactive conjugates.
Collapse
Affiliation(s)
- Stephen J Walsh
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK. and Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK
| | - Jessica Iegre
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
| | - Hikaru Seki
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
| | - Jonathan D Bargh
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
| | - Hannah F Sore
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
| | - Jeremy S Parker
- Early Chemical Development, Pharmaceutical Development, R&D, AstraZeneca, Macclesfield, UK
| | - Jason S Carroll
- Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK
| | - David R Spring
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
| |
Collapse
|
108
|
Zhang H, Zhou X, Liu D, Zhu Y, Ma Q, Zhang Y. Progress and challenges of personalized neoantigens in the clinical treatment of tumors. MEDICINE IN DRUG DISCOVERY 2020. [DOI: 10.1016/j.medidd.2020.100030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
|
109
|
Knauer S, Koch N, Uth C, Meusinger R, Avrutina O, Kolmar H. Sustainable Peptide Synthesis Enabled by a Transient Protecting Group. Angew Chem Int Ed Engl 2020; 59:12984-12990. [PMID: 32324944 PMCID: PMC7496111 DOI: 10.1002/anie.202003676] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Indexed: 01/22/2023]
Abstract
The growing interest in synthetic peptides has prompted the development of viable methods for their sustainable production. Currently, large amounts of toxic solvents are required for peptide assembly from protected building blocks, and switching to water as a reaction medium remains a major hurdle in peptide chemistry. We report an aqueous solid‐phase peptide synthesis strategy that is based on a water‐compatible 2,7‐disulfo‐9‐fluorenylmethoxycarbonyl (Smoc) protecting group. This approach enables peptide assembly under aqueous conditions, real‐time monitoring of building block coupling, and efficient postsynthetic purification. The procedure for the synthesis of all natural and several non‐natural Smoc‐protected amino acids is described, as well as the assembly of 22 peptide sequences and the fundamental issues of SPPS, including the protecting group strategy, coupling and cleavage efficiency, stability under aqueous conditions, and crucial side reactions.
Collapse
Affiliation(s)
- Sascha Knauer
- Sulfotools GmbH, In der Niederwiesen 24a, 64291, Darmstadt, Germany.,Institute for Organic Chemistry and Biochemistry, TU Darmstadt, Alarich-Weiss-Strasse 4, 64287, Darmstadt, Germany
| | - Niklas Koch
- Sulfotools GmbH, In der Niederwiesen 24a, 64291, Darmstadt, Germany
| | - Christina Uth
- Sulfotools GmbH, In der Niederwiesen 24a, 64291, Darmstadt, Germany
| | - Reinhard Meusinger
- Institute for Organic Chemistry and Biochemistry, TU Darmstadt, Alarich-Weiss-Strasse 4, 64287, Darmstadt, Germany
| | - Olga Avrutina
- Institute for Organic Chemistry and Biochemistry, TU Darmstadt, Alarich-Weiss-Strasse 4, 64287, Darmstadt, Germany
| | - Harald Kolmar
- Institute for Organic Chemistry and Biochemistry, TU Darmstadt, Alarich-Weiss-Strasse 4, 64287, Darmstadt, Germany
| |
Collapse
|
110
|
|
111
|
Amatya R, Park T, Hwang S, Yang J, Lee Y, Cheong H, Moon C, Kwak HD, Min KA, Shin MC. Drug Delivery Strategies for Enhancing the Therapeutic Efficacy of Toxin-Derived Anti-Diabetic Peptides. Toxins (Basel) 2020; 12:toxins12050313. [PMID: 32397648 PMCID: PMC7290885 DOI: 10.3390/toxins12050313] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 05/04/2020] [Accepted: 05/06/2020] [Indexed: 12/13/2022] Open
Abstract
Toxin peptides derived from the skin secretions of amphibians possess unique hypoglycemic activities. Many of these peptides share cationic and amphipathic structural similarities and appear to possess cell-penetrating abilities. The mechanism of their insulinotropic action is yet not elucidated, but they have shown great potential in regulating the blood glucose levels in animal models. Therefore, they have emerged as potential drug candidates as therapeutics for type 2 diabetes. Despite their anti-diabetic activity, there remain pharmaceutical challenges to be addressed for their clinical applications. Here, we present an overview of recent studies related to the toxin-derived anti-diabetic peptides derived from the skin secretions of amphibians. In the latter part, we introduce the bottleneck challenges for their delivery in vivo and general drug delivery strategies that may be applicable to extend their blood circulation time. We focus our research on the strategies that have been successfully applied to improve the plasma half-life of exendin-4, a clinically available toxin-derived anti-diabetic peptide drug.
Collapse
Affiliation(s)
- Reeju Amatya
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, 501 Jinju Daero, Jinju, Gyeongnam 52828, Korea; (R.A.); (T.P.)
| | - Taehoon Park
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, 501 Jinju Daero, Jinju, Gyeongnam 52828, Korea; (R.A.); (T.P.)
| | - Seungmi Hwang
- College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, 197 Injero, Gimhae, Gyeongnam 50834, Korea;
| | - JaeWook Yang
- Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine, 75 Bokjiro, Busanjin-gu, Busan 47392, Korea; (J.Y.); (H.D.K.)
- T2B Infrastructure Center for Ocular Disease, Inje University Busan Paik Hospital, 81 Jinsaro 83 Beon-gil, Busanjin-gu, Busan 47397, Korea;
| | - Yoonjin Lee
- T2B Infrastructure Center for Ocular Disease, Inje University Busan Paik Hospital, 81 Jinsaro 83 Beon-gil, Busanjin-gu, Busan 47397, Korea;
| | - Heesun Cheong
- Division of Cancer Biology, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Korea;
| | - Cheol Moon
- College of Pharmacy, Sunchon National University, 255 Jungang-ro, Suncheon, Jeonnam 57922, Korea;
| | - Hyun Duck Kwak
- Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine, 75 Bokjiro, Busanjin-gu, Busan 47392, Korea; (J.Y.); (H.D.K.)
| | - Kyoung Ah Min
- College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, 197 Injero, Gimhae, Gyeongnam 50834, Korea;
- Correspondence: (K.A.M.); (M.C.S.); Tel.: +82-55-320-3459 (K.A.M.); +82-55-772-2429 (M.C.S.)
| | - Meong Cheol Shin
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, 501 Jinju Daero, Jinju, Gyeongnam 52828, Korea; (R.A.); (T.P.)
- Correspondence: (K.A.M.); (M.C.S.); Tel.: +82-55-320-3459 (K.A.M.); +82-55-772-2429 (M.C.S.)
| |
Collapse
|
112
|
Abstract
The development of peptide-based drugs, which are usually synthetic analogues of endogenous peptides, is currently one of the most topical directions in drug development. Among them, antitumor peptide-based drugs are of great interest. Anticancer peptides can be classified into three main groups based on their mechanism of action: inhibitory, necrosis-inducing and pro-apoptotic peptides. As an antitumor therapy, peptides are considered to have at least the same efficacy as chemotherapy or surgical treatment, but offer advantages in terms of safety and tolerability, given that chemotherapy is usually characterized by severe adverse effects, and surgery carries additional risks for patients. Short peptides have a number of benefits over other molecules. First, compared with full-length proteins and antibodies, short peptides are less immunogenic, more stable ex-vivo (prolonged storage at room temperature), and have better tumor or organ permeability. Moreover, the production of such short peptide-based drugs is more cost effective. Second, in comparison with small organic molecules, peptides have higher efficacy and specificity. Finally, due to the fact that the main products of peptide metabolism are amino acids, these drugs are usually characterized by lower toxicity. Short peptides have a highly selective mechanism of action, thereby demonstrating low toxicity. Furthermore, with the addition of different stabilizing structural modifications, as well as novel drug delivery systems, the peptide-based drugs are proving to be promising therapeutics for cancer mono- or polytherapy. However, challenges remain including that endogenous and synthetic peptide molecules can be oncogenic. Therefore, it is important to investigate whether peptides contribute to tumor growth. In order to answer such questions, numerous preclinical and clinical studies of peptide-based therapeutics are currently being conducted.
Collapse
|
113
|
Zhou J, Walker J, Ackermann R, Olsen K, Hong JKY, Wang Y, Schwendeman SP. Effect of Manufacturing Variables and Raw Materials on the Composition-Equivalent PLGA Microspheres for 1-Month Controlled Release of Leuprolide. Mol Pharm 2020; 17:1502-1515. [PMID: 32074448 DOI: 10.1021/acs.molpharmaceut.9b01188] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The 1-month Lupron Depot (LD) is a 75/25 acid-capped poly(lactic-co-glycolic acid) (PLGA) microsphere product encapsulating water-soluble leuprolide acetate with no generic products available in the U.S. Composition-equivalent PLGA microsphere formulations to the LD as a function of raw material and manufacturing variables were developed by using the solvent evaporation encapsulation method. The following variables were adjusted: polymer supplier/polymerization type, gelatin supplier/bloom number, polymer concentration, first homogenization speed and time, volume of primary water phase, second homogenization time, volume of secondary water phase, and stirring rate. The loading and encapsulation efficiency (EE) of leuprolide and gelatin were determined to identify a large number of composition-equivalent formulations within a ±10% specification of the LD. Key physical-chemical properties of the formulations (e.g., morphology, particle size distribution, glass transition temperature (Tg), residual moisture and solvent, and porosity) were characterized to determine the effect of manufacturing variables on the product attributes. The EE of gelatin across all formulations prepared (101 ± 1%) was observed to be much higher than the EE of leuprolide (57 ± 1%). Judicious adjustment of polymer concentration, second homogenization time, and volume of second water phase was key to achieving high EE of leuprolide, although EE higher than 70% was not easily achievable owing to the difficulty of emulsifying highly viscous primary emulsion into homogeneous small droplets that could prevent peptide loss during the second homogenization under the conditions and equipment used. The in vitro release kinetics of the formulations was highly similar to the LD in a zero-order manner after ∼20% initial burst release, indicating a critical role of the composition on peptide release in this formulation. The characterization of composition-equivalent formulations described here could be useful for further development of generic leuprolide PLGA microspheres and for guiding decisions on the influence of process variables on product physicochemical attributes and release performance.
Collapse
Affiliation(s)
- Jia Zhou
- Department of Pharmaceutical Sciences, The Biointerfaces Institute, University of Michigan, 2800 Plymouth Road, Ann Arbor, Michigan 48109, United States
| | - Jennifer Walker
- Department of Pharmaceutical Sciences, The Biointerfaces Institute, University of Michigan, 2800 Plymouth Road, Ann Arbor, Michigan 48109, United States
| | - Rose Ackermann
- Department of Pharmaceutical Sciences, The Biointerfaces Institute, University of Michigan, 2800 Plymouth Road, Ann Arbor, Michigan 48109, United States
| | - Karl Olsen
- Department of Pharmaceutical Sciences, The Biointerfaces Institute, University of Michigan, 2800 Plymouth Road, Ann Arbor, Michigan 48109, United States
| | - Justin K Y Hong
- Department of Pharmaceutical Sciences, The Biointerfaces Institute, University of Michigan, 2800 Plymouth Road, Ann Arbor, Michigan 48109, United States
| | - Yan Wang
- Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993, United States
| | - Steven P Schwendeman
- Department of Pharmaceutical Sciences, The Biointerfaces Institute, University of Michigan, 2800 Plymouth Road, Ann Arbor, Michigan 48109, United States.,Department of Biomedical Engineering, University of Michigan, 2200 Bonisteel Boulevard, Ann Arbor, Michigan 48109, United States
| |
Collapse
|
114
|
Hebbi V, Kumar D, Rathore AS. Process intensification in peptide manufacturing: Recombinant lethal toxin neutralizing factor (rLTNF) as a case study. Process Biochem 2020. [DOI: 10.1016/j.procbio.2019.10.036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
115
|
Hemker AK, Nguyen LT, Karwe M, Salvi D. Effects of pressure-assisted enzymatic hydrolysis on functional and bioactive properties of tilapia (Oreochromis niloticus) by-product protein hydrolysates. Lebensm Wiss Technol 2020. [DOI: 10.1016/j.lwt.2019.109003] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
116
|
Bechaux J, Gatellier P, Le Page JF, Drillet Y, Sante-Lhoutellier V. A comprehensive review of bioactive peptides obtained from animal byproducts and their applications. Food Funct 2020; 10:6244-6266. [PMID: 31577308 DOI: 10.1039/c9fo01546a] [Citation(s) in RCA: 63] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Livestock generates high quantities of residues, which has become a major socioeconomic issue for the meat industry. This review focuses on the identification of bioactive peptides (BPs) in animal byproducts and meat wastes. Firstly, the main bioactivities that peptides can have will be described and the methods for their evaluation will be discussed. Secondly, the various origins of these BPs will be studied. Then, the techniques and tools for the generation of BPs will be detailed in order to discuss, in the final part, how peptides could be used and assimilated. BPs possess diverse biological activities and can be strategic candidates for substituting synthetic molecules. In silico potentiality studies are a helpful tool to understand and predict BPs released from proteins and their potential activities. However, in vitro validation is often required. Although BP use is compelled by strict regulations in relation to the field of application, they are also limited by their low bioavailability and bioaccessibility. Therefore, it is important to test peptide stability during gastrointestinal digestion. Protective strategies have been discussed since their use could improve the stability and effectiveness of BPs.
Collapse
Affiliation(s)
- Julia Bechaux
- INRA, UR 370, Qualité des Produits Animaux (QuaPA), Site de Theix, 63122, Saint-Genès Champanelle, France.
| | | | | | | | | |
Collapse
|
117
|
Affiliation(s)
- Francesco De Riccardis
- Department of Chemistry and Biology “A. Zambelli”; University of Salerno; Via Giovani Paolo II, 132 84084 Fisciano SA Italy
| |
Collapse
|
118
|
Dubey SK, Alexander A, Pradhyut KS, Agrawal M, Jain R, Saha RN, Singhvi G, Saraf S, Saraf S. Recent Avenues in Novel Patient-Friendly Techniques for the Treatment of Diabetes. Curr Drug Deliv 2020; 17:3-14. [DOI: 10.2174/1567201816666191106102020] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Revised: 09/14/2019] [Accepted: 10/15/2019] [Indexed: 12/26/2022]
Abstract
Background:
Diabetes is one of the most common chronic metabolic disorders which affect
the quality of human life worldwide. As per the WHO report, between 1980 to 2014, the number of
diabetes patients increases from 108 million to 422 million, with a global prevalence rate of 8.5% per
year. Diabetes is the prime reason behind various other diseases like kidney failure, stroke, heart disorders,
glaucoma, etc. It is recognized as the seventh leading cause of death throughout the world. The
available therapies are painful (insulin injections) and inconvenient due to higher dosing frequency.
Thus, to find out a promising and convenient treatment, extensive investigations are carried out globally
by combining novel carrier system (like microparticle, microneedle, nanocarrier, microbeads etc.) and
delivery devices (insulin pump, stimuli-responsive device, inhalation system, bioadhesive patch, insulin
pen etc.) for more precise diagnosis and painless or less invasive treatment of disease.
Objective:
The review article is made with an objective to compile information about various upcoming
and existing modern technologies developed to provide greater patient compliance and reduce the undesirable
side effect of the drug. These devices evade the necessity of daily insulin injection and offer a
rapid onset of action, which sustained for a prolonged duration of time to achieve a better therapeutic
effect.
Conclusion:
Despite numerous advantages, various commercialized approaches, like Afrezza (inhalation
insulin) have been a failure in recent years. Such results call for more potential work to develop a
promising system. The novel approaches range from the delivery of non-insulin blood glucose lowering
agents to insulin-based therapy with minimal invasion are highly desirable.
Collapse
Affiliation(s)
- Sunil Kumar Dubey
- Department of Pharmacy, Faculty of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India
| | - Amit Alexander
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER GUWAHATI), Ministry of Chemicals & Fertilizers, Govt. of India, NH 37, NITS Mirza, Kamrup- 781125, Guwahati (Assam), India
| | - K. Sai Pradhyut
- Department of Pharmacy, Faculty of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India
| | - Mukta Agrawal
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER GUWAHATI), Ministry of Chemicals & Fertilizers, Govt. of India, NH 37, NITS Mirza, Kamrup- 781125, Guwahati (Assam), India
| | - Rupesh Jain
- Department of Pharmacy, Faculty of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India
| | - Ranendra Narayana Saha
- Department of Biotechnology, Faculty of Biotechnology, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Dubai Campus, Dubai, United Arab Emirates
| | - Gautam Singhvi
- Department of Pharmacy, Faculty of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India
| | - Swarnlata Saraf
- University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh 492 010, India
| | - Shailendra Saraf
- University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh 492 010, India
| |
Collapse
|
119
|
Afonin S, Babii O, Reuter A, Middel V, Takamiya M, Strähle U, Komarov IV, Ulrich AS. Light-controllable dithienylethene-modified cyclic peptides: photoswitching the in vivo toxicity in zebrafish embryos. Beilstein J Org Chem 2020; 16:39-49. [PMID: 31976015 PMCID: PMC6964649 DOI: 10.3762/bjoc.16.6] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Accepted: 12/17/2019] [Indexed: 12/21/2022] Open
Abstract
This study evaluates the embryotoxicity of dithienylethene-modified peptides upon photoswitching, using 19 analogues based on the β-hairpin scaffold of the natural membranolytic peptide gramicidin S. We established an in vivo assay in two variations (with ex vivo and in situ photoisomerization), using larvae of the model organism Danio rerio, and determined the toxicities of the peptides in terms of 50% lethal doses (LD50). This study allowed us to: (i) demonstrate the feasibility of evaluating peptide toxicity with D. rerio larvae at 3–4 days post fertilization, (ii) determine the phototherapeutic safety windows for all peptides, (iii) demonstrate photoswitching of the whole-body toxicity for the dithienylethene-modified peptides in vivo, (iv) re-analyze previous structure–toxicity relationship data, and (v) select promising candidates for potential clinical development.
Collapse
Affiliation(s)
- Sergii Afonin
- Institute of Biological Interfaces (IBG-2), Karlsruhe Institute of Technology (KIT), POB 3640, 76021 Karlsruhe, Germany
| | - Oleg Babii
- Institute of Biological Interfaces (IBG-2), Karlsruhe Institute of Technology (KIT), POB 3640, 76021 Karlsruhe, Germany
| | - Aline Reuter
- Institute of Organic Chemistry (IOC), KIT, Fritz-Haber-Weg 6, 76131 Karlsruhe, Germany
| | - Volker Middel
- Institute of Toxicology and Genetics (ITG), KIT, POB 3640, 76021 Karlsruhe, Germany
| | - Masanari Takamiya
- Institute of Toxicology and Genetics (ITG), KIT, POB 3640, 76021 Karlsruhe, Germany
| | - Uwe Strähle
- Institute of Toxicology and Genetics (ITG), KIT, POB 3640, 76021 Karlsruhe, Germany
| | - Igor V Komarov
- Taras Shevchenko National University of Kyiv, vul. Volodymyrska 60, 1601 Kyiv, Ukraine.,Lumobiotics GmbH, Auerstr. 2, 76227 Karlsruhe, Germany
| | - Anne S Ulrich
- Institute of Biological Interfaces (IBG-2), Karlsruhe Institute of Technology (KIT), POB 3640, 76021 Karlsruhe, Germany.,Institute of Organic Chemistry (IOC), KIT, Fritz-Haber-Weg 6, 76131 Karlsruhe, Germany
| |
Collapse
|
120
|
Raheem N, Straus SK. Mechanisms of Action for Antimicrobial Peptides With Antibacterial and Antibiofilm Functions. Front Microbiol 2019; 10:2866. [PMID: 31921046 PMCID: PMC6927293 DOI: 10.3389/fmicb.2019.02866] [Citation(s) in RCA: 199] [Impact Index Per Article: 39.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2019] [Accepted: 11/27/2019] [Indexed: 12/14/2022] Open
Abstract
The antibiotic crisis has led to a pressing need for alternatives such as antimicrobial peptides (AMPs). Recent work has shown that these molecules have great potential not only as antimicrobials, but also as antibiofilm agents, immune modulators, anti-cancer agents and anti-inflammatories. A better understanding of the mechanism of action (MOA) of AMPs is an important part of the discovery of more potent and less toxic AMPs. Many models and techniques have been utilized to describe the MOA. This review will examine how biological assays and biophysical methods can be utilized in the context of the specific antibacterial and antibiofilm functions of AMPs.
Collapse
Affiliation(s)
- Nigare Raheem
- Department of Chemistry, The University of British Columbia, Vancouver, BC, Canada
| | - Suzana K Straus
- Department of Chemistry, The University of British Columbia, Vancouver, BC, Canada
| |
Collapse
|
121
|
Freire DO, da Cunha NB, Leite ML, Kostopoulos AGC, da Silva SNB, Souza ACB, Nolasco DO, Franco OL, Mortari MR, Dias SC. Wasp venom peptide, synoeca‐MP, fromSynoeca surinamashows antimicrobial activity against human and animal pathogenic microorganisms. Pept Sci (Hoboken) 2019. [DOI: 10.1002/pep2.24141] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Daniel O. Freire
- Neuropharmacology Laboratory, Department of Physiological SciencesInstitute of Biological Sciences, University of Brasilia Brasilia Brazil
| | - Nicolau B. da Cunha
- Centro de Análise Proteômicas e Bioquímicas de BrasíliaUniversidade Católica de Brasília Brasília Brazil
| | - Michel L. Leite
- Centro de Análise Proteômicas e Bioquímicas de BrasíliaUniversidade Católica de Brasília Brasília Brazil
| | - Alessandra G. C. Kostopoulos
- Neuropharmacology Laboratory, Department of Physiological SciencesInstitute of Biological Sciences, University of Brasilia Brasilia Brazil
| | - Sheila N. B. da Silva
- Centro de Análise Proteômicas e Bioquímicas de BrasíliaUniversidade Católica de Brasília Brasília Brazil
| | - Adolfo C. B. Souza
- Neuropharmacology Laboratory, Department of Physiological SciencesInstitute of Biological Sciences, University of Brasilia Brasilia Brazil
| | - Diego O. Nolasco
- Centro de Análise Proteômicas e Bioquímicas de BrasíliaUniversidade Católica de Brasília Brasília Brazil
| | - Octávio L. Franco
- Centro de Análise Proteômicas e Bioquímicas de BrasíliaUniversidade Católica de Brasília Brasília Brazil
- S‐Inova Biotech, Pós‐graduação em BiotecnologiaUniversidade Católica Dom Bosco Campo Grande Brazil
| | - Márcia R. Mortari
- Neuropharmacology Laboratory, Department of Physiological SciencesInstitute of Biological Sciences, University of Brasilia Brasilia Brazil
- Universidade de Brasília, Pós‐Graduação em Biologia Animal, Campus Universitário Darcy Ribeiro Brasília Brazil
| | - Simoni C. Dias
- Centro de Análise Proteômicas e Bioquímicas de BrasíliaUniversidade Católica de Brasília Brasília Brazil
| |
Collapse
|
122
|
Seyfi R, Kahaki FA, Ebrahimi T, Montazersaheb S, Eyvazi S, Babaeipour V, Tarhriz V. Antimicrobial Peptides (AMPs): Roles, Functions and Mechanism of Action. Int J Pept Res Ther 2019. [DOI: 10.1007/s10989-019-09946-9] [Citation(s) in RCA: 59] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
123
|
Li L, Ma S, Qin Y, Liu L. Enhanced UHPLC-MS/MS determination of a therapeutic heptapeptide mimic for inflammatory-related diseases in rat plasma: application to a pharmacokinetic study. RSC Adv 2019; 9:32699-32711. [PMID: 35529728 PMCID: PMC9073091 DOI: 10.1039/c9ra05114g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Accepted: 09/21/2019] [Indexed: 11/21/2022] Open
Abstract
The seven amino acid peptide, GQTYTSG (named as SP), a peptide mimic derived from hypervariable region 1 (HVR1) of the hepatitis C virus (HCV) has presented remarkable anti-inflammatory activities in previous experiments, indicating that it could be a novel therapeutic peptide candidate for different inflammation-related diseases, such as HCV infection and asthma. A heptapeptide mimic discovery study highlighted the need for the development of quantitative bioanalytical assays for measuring the levels of SP. Herein, a reliable and sensitive ultrahigh-performance liquid chromatography (UHPLC) with tandem mass spectrometry (MS/MS) assay was established and validated for the determination of SP in rat plasma. C-11, with two amino acid substitutions compared to SP (Glycine 1 and Glycine 7) and a disulfide, acted as an internal standard (IS). SP and C-11 were isolated from acidified plasma using protein precipitation and the extracts were analyzed by reversed-phase UHPLC-MS/MS detection. We used an SHIM-PACK GISS C18 (2.1 × 100 mm, 1.9 μm) column with water containing 0.2% acetic acid as the aqueous mobile phase and methanol as the organic mobile phase with a 0.3 mL min-1 flow rate. We used an AB SCIEX TripleQuad™ 5500 mass spectrometer equipped with a TurboIon Spray interface and operated it in positive-ion mode. Multiple reaction monitoring (MRM) was used for the quantification of the precursor to the product ion at m/z 713.3 → 432.2 for SP and m/z 803.2 → 539.1 for IS. The method was fully validated according to the US Food and Drug Administration (FDA) guideline (2018), and provided satisfactory accuracy, precision, and reproducibility for the quantification of SP in rat plasma. Excellent linearity was achieved (r > 0.9977) over a linear dynamic range of 0.1-200 ng mL-1 with a lower limit of quantification (LLOQ) of 0.1 ng mL-1. The validated assay was applied to gain the pharmacokinetic (PK) parameters and the concentration-time profile for SP after subcutaneous administration in rats.
Collapse
Affiliation(s)
- Liang Li
- Center for Pharmacological Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry Shanghai 200437 PR China +8621-65043855
- State Key Laboratory of New Drug and Pharmaceutical Process Shanghai 201203 PR China
- Shanghai Professional and Technical Service Center for Biological Material Drug-Ability Evaluation Shanghai 200437 PR China
| | - Shumei Ma
- Department of Pharmacology, School of Pharmacy, Fudan University Shanghai 201203 PR China
| | - Yan Qin
- Center for Pharmacological Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry Shanghai 200437 PR China +8621-65043855
- State Key Laboratory of New Drug and Pharmaceutical Process Shanghai 201203 PR China
- Shanghai Professional and Technical Service Center for Biological Material Drug-Ability Evaluation Shanghai 200437 PR China
| | - Li Liu
- Center for Pharmacological Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry Shanghai 200437 PR China +8621-65043855
- State Key Laboratory of New Drug and Pharmaceutical Process Shanghai 201203 PR China
- Shanghai Professional and Technical Service Center for Biological Material Drug-Ability Evaluation Shanghai 200437 PR China
| |
Collapse
|
124
|
Heyl DL, Iwaniec B, Esckilsen D, Price D, Guttikonda P, Cooper J, Lombardi J, Milletti M, Evans HG. Using Small Peptide Segments of Amyloid-β and Humanin to Examine their Physical Interactions. Protein Pept Lett 2019; 26:502-511. [PMID: 30950343 DOI: 10.2174/0929866526666190405122117] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Revised: 03/20/2019] [Accepted: 03/21/2019] [Indexed: 12/22/2022]
Abstract
BACKGROUND Amyloid fibrils in Alzheimer's disease are composed of amyloid-β (Aβ) peptides of variant lengths. Humanin (HN), a 24 amino acid residue neuroprotective peptide, is known to interact with the predominant Aβ isoform in the brain, Aβ (1-40). METHODS Here, we constructed smaller segments of Aβ and HN and identified residues in HN important for both HN-HN and HN-Aβ interactions. Peptides corresponding to amino acid residues 5- 15 of HN, HN (5-15), HN (5-15, L11S), where Leu11 was replaced with Ser, and residues 17-28 of Aβ, Aβ (17-28), were synthesized and tested for their ability to block formation of the complex between HN and Aβ (1-40). RESULTS Co-immunoprecipitation and binding kinetics showed that HN (5-15) was more efficient at blocking the complex between HN and Aβ (1-40) than either HN (5-15, L11S) or Aβ (17-28). Binding kinetics of these smaller peptides with either full-length HN or Aβ (1-40) showed that HN (5- 15) was able to bind either Aβ (1-40) or HN more efficiently than HN (5-15, L11S) or Aβ (17-28). Compared to full-length HN, however, HN (5-15) bound Aβ (1-40) with a weaker affinity suggesting that while HN (5-15) binds Aβ, other residues in the full length HN peptide are necessary for maximum interactions. CONCLUSION L11 was more important for interactions with Aβ (1-40) than with HN. Aβ (17-28) was relatively ineffective at binding to either Aβ (1-40) or HN. Moreover, HN, and the smaller HN (5-15), HN (5-15 L11S), and Aβ (17-28) peptides, had different effects on regulating Aβ (1-40) aggregation kinetics.
Collapse
Affiliation(s)
- Deborah L Heyl
- Department of Chemistry, Eastern Michigan University, Ypsilanti, MI 48197, United States
| | - Brandon Iwaniec
- Department of Chemistry, Eastern Michigan University, Ypsilanti, MI 48197, United States
| | - Daniel Esckilsen
- Department of Chemistry, Eastern Michigan University, Ypsilanti, MI 48197, United States
| | - Deanna Price
- Department of Chemistry, Eastern Michigan University, Ypsilanti, MI 48197, United States
| | - Prathyusha Guttikonda
- Department of Chemistry, Eastern Michigan University, Ypsilanti, MI 48197, United States
| | - Jennifer Cooper
- Department of Chemistry, Eastern Michigan University, Ypsilanti, MI 48197, United States
| | - Julia Lombardi
- Department of Chemistry, Eastern Michigan University, Ypsilanti, MI 48197, United States
| | - Maria Milletti
- Department of Chemistry, Eastern Michigan University, Ypsilanti, MI 48197, United States
| | - Hedeel Guy Evans
- Department of Chemistry, Eastern Michigan University, Ypsilanti, MI 48197, United States
| |
Collapse
|
125
|
Abstract
Abstract
An increasing problem in the field of health protection is the emergence of drug-resistant and multi-drug-resistant bacterial strains. They cause a number of infections, including hospital infections, which currently available antibiotics are unable to fight. Therefore, many studies are devoted to the search for new therapeutic agents with bactericidal and bacteriostatic properties. One of the latest concepts is to search for this type of substances among toxins produced by venomous animals. In this approach, however, special attention is paid to snake venom because it contains molecules with antibacterial properties. Thorough investigations have shown that the phospholipases A2 (PLA2) and l-amino acids oxidases (LAAO), as well as fragments of these enzymes, are mainly responsible for the bactericidal properties of snake venoms. Some preliminary research studies also suggest that fragments of three-finger toxins (3FTx) are bactericidal. It has also been proven that some snakes produce antibacterial peptides (AMP) homologous to human defensins and cathelicidins. The presence of these proteins and peptides means that snake venoms continue to be an interesting material for researchers and can be perceived as a promising source of antibacterial agents.
Collapse
|
126
|
Aaghaz S, Gohel V, Kamal A. Peptides as Potential Anticancer Agents. Curr Top Med Chem 2019; 19:1491-1511. [DOI: 10.2174/1568026619666190125161517] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2018] [Revised: 12/26/2018] [Accepted: 01/18/2019] [Indexed: 12/21/2022]
Abstract
Cancer consists of heterogeneous multiple cell subpopulation which at a later stage develop resistant phenotypes, which include resistance to pro-apoptotic stimuli and/or cytotoxic resistance to anticancer compounds. The property of cancerous cells to affect almost any part of the body categorizes cancer to many anatomic and molecular subtypes, each requiring a particular therapeutic intervention. As several modalities are hindered in a variety of cancers and as the cancer cells accrue varied types of oncogenic mutations during their progression the most likely benefit will be obtained by a combination of therapeutic agents that might address the diverse hallmarks of cancer. Natural compounds are the backbone of cancer therapeutics owing to their property of affecting the DNA impairment and restoration mechanisms and also the gene expression modulated via several epigenetic molecular mechanisms. Bioactive peptides isolated from flora and fauna have transformed the arena of antitumour therapy and prompt progress in preclinical studies is promising. The difficulties in creating ACP rest in improving its delivery to the tumour site and it also must maintain a low toxicity profile. The substantial production costs, low selectivity and proteolytic stability of some ACP are some of the factors hindering the progress of peptide drug development. Recently, several publications have tried to edify the field with the idea of using peptides as adjuvants with established drugs for antineoplastic use. This review focuses on peptides from natural sources that precisely target tumour cells and subsequently serve as anticancer agents that are less toxic to normal tissues.
Collapse
Affiliation(s)
- Shams Aaghaz
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar, Mohali, India
| | - Vivek Gohel
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar, Mohali, India
| | - Ahmed Kamal
- School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi, India
| |
Collapse
|
127
|
Mohan NM, Zorgani A, Jalowicki G, Kerr A, Khaldi N, Martins M. Unlocking NuriPep 1653 From Common Pea Protein: A Potent Antimicrobial Peptide to Tackle a Pan-Drug Resistant Acinetobacter baumannii. Front Microbiol 2019; 10:2086. [PMID: 31620099 PMCID: PMC6759681 DOI: 10.3389/fmicb.2019.02086] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Accepted: 08/23/2019] [Indexed: 12/22/2022] Open
Abstract
While the antibiotic era has come and gone, antimicrobial peptides (AMPs) hold promise as novel therapies to treat multidrug resistant (MDR) pathogens in an age where the threat of multidrug resistance escalates worldwide. Here, we report the bactericidal properties of NuriPep 1653, a novel 22 mer and non-modified peptide. NuriPep 1653 was identified within the sequence of the non-antimicrobial P54 protein, which is involved in nutrient reservoir activity in Pisum sativum. Total bacterial clearance of Acinetobacter baumannii cells (1 × 108 cells/mL) was observed using only 4 × MIC (48 μg/mL) of NuriPep 1653 after just 20 min of treatment. We uncovered a synergistic interaction between NuriPep 1653 and another antimicrobial peptide, colistin. The MIC of NuriPep 1653 and colistin dropped from 12 and 8 μg/mL to 2 and 1 μg/mL, respectively, when they were combined. NuriPep 1653 exhibits no cytotoxicity in different human cell lines and has a low propensity to induce bacterial resistance in a colistin resistant clinical isolate of A. baumannii. The existence of these peptides embedded in proteins unearths potentially new classes of antimicrobials with activity against clinically relevant pathogens. Our findings push the boundaries of traditional peptide discovery and represent a leading edge for natural bioactive compounds which may have a common existence in nature but remain unexposed.
Collapse
Affiliation(s)
- Niamh Maire Mohan
- Department of Microbiology, Moyne Institute of Preventive Medicine, School of Genetics and Microbiology, Trinity College Dublin, University of Dublin, Dublin, Ireland
- Nuritas Limited, Dublin, Ireland
| | | | | | | | | | - Marta Martins
- Department of Microbiology, Moyne Institute of Preventive Medicine, School of Genetics and Microbiology, Trinity College Dublin, University of Dublin, Dublin, Ireland
| |
Collapse
|
128
|
Adhikari S, Leissa JA, Karlsson AJ. Beyond function: Engineering improved peptides for therapeutic applications. AIChE J 2019. [DOI: 10.1002/aic.16776] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Sayanee Adhikari
- Department of Chemical and Biomolecular Engineering University of Maryland College Park Maryland
| | - Jesse A. Leissa
- Department of Chemical and Biomolecular Engineering University of Maryland College Park Maryland
| | - Amy J. Karlsson
- Department of Chemical and Biomolecular Engineering University of Maryland College Park Maryland
- Fischell Department of Bioengineering University of Maryland College Park Maryland
| |
Collapse
|
129
|
Ansar S, Vetrivel U. PepVis: An integrated peptide virtual screening pipeline for ensemble and flexible docking protocols. Chem Biol Drug Des 2019; 94:2041-2050. [DOI: 10.1111/cbdd.13607] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2019] [Revised: 08/06/2019] [Accepted: 08/10/2019] [Indexed: 01/06/2023]
Affiliation(s)
- Samdani Ansar
- Centre for Bioinformatics Kamalnayan Bajaj Institute for Research in Vision and Ophthalmology Vision Research Foundation Sankara Nethralaya Chennai India
- School of Chemical and Biotechnology SASTRA Deemed University Thanjavur India
| | - Umashankar Vetrivel
- Centre for Bioinformatics Kamalnayan Bajaj Institute for Research in Vision and Ophthalmology Vision Research Foundation Sankara Nethralaya Chennai India
| |
Collapse
|
130
|
Al Musaimi O, El-Faham A, Basso A, de la Torre BG, Albericio F. γ-Valerolactone (GVL): An eco-friendly anchoring solvent for solid-phase peptide synthesis. Tetrahedron Lett 2019. [DOI: 10.1016/j.tetlet.2019.151058] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
131
|
Tanhaeian A, Habibi Najafi MB, Rahnama P, Azghandi M. Production of a Recombinant Peptide (Lasioglossin LL ΙΙΙ) and Assessment of Antibacterial and Antioxidant Activity. Int J Pept Res Ther 2019. [DOI: 10.1007/s10989-019-09904-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
132
|
Patil SP, Goswami A, Kalia K, Kate AS. Plant-Derived Bioactive Peptides: A Treatment to Cure Diabetes. Int J Pept Res Ther 2019; 26:955-968. [PMID: 32435169 PMCID: PMC7223764 DOI: 10.1007/s10989-019-09899-z] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/18/2019] [Indexed: 12/17/2022]
Abstract
ABSTRACT Recent advances in analytical techniques have opened new opportunities for plant-based drug discovery in the field of peptide and proteins. Enzymatic hydrolysis of plant parent proteins forms bioactive peptides which are explored in the treatment of various diseases. In this review, we will discuss the identified plant-based bioactive proteins and peptides and the in vitro, in vivo results for the treatment of diabetes. Extraction, isolation, characterization and commercial utilization of plant proteins is a challenge for the pharmaceutical industry as plants contain several interfering secondary metabolites. The market of peptide drugs for the treatment of diabetes is growing at a fast rate. Plant-based bioactive peptides might open up new opportunities to discover economic lead for the management of various diseases. GRAPHIC ABSTRACT
Collapse
Affiliation(s)
- Shital P. Patil
- Department of Natural Products, National Institute of Pharmaceutical Education and Research, Ahmedabad, Gujarat India
| | - Ashutosh Goswami
- Department of Natural Products, National Institute of Pharmaceutical Education and Research, Ahmedabad, Gujarat India
| | - Kiran Kalia
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Ahmedabad, Gujarat India
| | - Abhijeet S. Kate
- Department of Natural Products, National Institute of Pharmaceutical Education and Research, Ahmedabad, Gujarat India
| |
Collapse
|
133
|
Dos Santos AP, de Araújo TG, Rádis-Baptista G. Nanoparticles Functionalized with Venom-Derived Peptides and Toxins for Pharmaceutical Applications. Curr Pharm Biotechnol 2019; 21:97-109. [PMID: 31223083 DOI: 10.2174/1389201020666190621104624] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2019] [Revised: 04/17/2019] [Accepted: 05/08/2019] [Indexed: 12/30/2022]
Abstract
Venom-derived peptides display diverse biological and pharmacological activities, making them useful in drug discovery platforms and for a wide range of applications in medicine and pharmaceutical biotechnology. Due to their target specificities, venom peptides have the potential to be developed into biopharmaceuticals to treat various health conditions such as diabetes mellitus, hypertension, and chronic pain. Despite the high potential for drug development, several limitations preclude the direct use of peptides as therapeutics and hamper the process of converting venom peptides into pharmaceuticals. These limitations include, for instance, chemical instability, poor oral absorption, short halflife, and off-target cytotoxicity. One strategy to overcome these disadvantages relies on the formulation of bioactive peptides with nanocarriers. A range of biocompatible materials are now available that can serve as nanocarriers and can improve the bioavailability of therapeutic and venom-derived peptides for clinical and diagnostic application. Examples of isolated venom peptides and crude animal venoms that have been encapsulated and formulated with different types of nanomaterials with promising results are increasingly reported. Based on the current data, a wealth of information can be collected regarding the utilization of nanocarriers to encapsulate venom peptides and render them bioavailable for pharmaceutical use. Overall, nanomaterials arise as essential components in the preparation of biopharmaceuticals that are based on biological and pharmacological active venom-derived peptides.
Collapse
Affiliation(s)
- Ana P Dos Santos
- Program of Post-graduation in Pharmaceutical Sciences (FFEO/UFC), Federal University of Ceara, Ceara, Brazil
| | | | | |
Collapse
|
134
|
Fili S, Valmas A, Spiliopoulou M, Kontou P, Fitch A, Beckers D, Degen T, Barlos K, Barlos KK, Karavassili F, Margiolaki I. Revisiting the structure of a synthetic somatostatin analogue for peptide drug design. ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE CRYSTAL ENGINEERING AND MATERIALS 2019; 75:611-620. [DOI: 10.1107/s2052520619006012] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Accepted: 04/30/2019] [Indexed: 11/10/2022]
Abstract
Natural or artificially manufactured peptides attract scientific interest worldwide owing to their wide array of pharmaceutical and biological activities. X-ray structural studies are used to provide a precise extraction of information, which can be used to enable a better understanding of the function and physicochemical characteristics of peptides. Although it is vulnerable to disassociation, one of the most vital human peptide hormones, somatostatin, plays a regulatory role in the endocrine system as well as in the release of numerous secondary hormones. This study reports the successful crystallization and complete structural model of octreotide, a stable octapeptide analogue of somatostatin. Common obstacles in crystallographic studies arising from the intrinsic difficulties of obtaining a suitable single-crystal specimen were efficiently overcome as polycrystalline material was employed for synchrotron and laboratory X-ray powder diffraction (XPD) measurements. Data collection and preliminary analysis led to the identification of unit-cell symmetry [orthorhombic, P212121, a = 18.5453 (15), b = 30.1766 (25), c = 39.798 (4) Å], a process which was later followed by complete structure characterization and refinement, underlying the efficacy of the suggested (XPD) approach.
Collapse
|
135
|
Ma C, Chen M, Chu W, Tao J, Kong D, Zhang M, Feng W. A Practical and Total Synthesis of Pasireotide: Synthesis of Cyclic Hexapeptide via a Three-Component Condensation. Molecules 2019; 24:molecules24112185. [PMID: 31212595 PMCID: PMC6600510 DOI: 10.3390/molecules24112185] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 05/29/2019] [Accepted: 06/04/2019] [Indexed: 11/16/2022] Open
Abstract
Pasireotide is a multi-receptor ligand somatostatin analogue approved for medical treatment of Cushing’s disease and acromegaly. The liquid-phase total synthesis of pasireotide-a 18-membered cyclic hexapeptide-was achieved by the 3 + 2 + 1 strategy, and the Pro1-Phe6 peptide bond was selected as the final cyclization position. Two key fragments were simply synthesized using N,O-bis(trimethylsilyl)acetamide/N-hydroxysuccinimide ester (BSA/NHS) as coupling agents, and processes of the two key fragments were simple without any chromatographic purification. The current synthesis method is easily scalable and produces the target peptide with an overall yield of 15%.
Collapse
Affiliation(s)
- Chunying Ma
- Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
| | - Miao Chen
- Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
| | - Weiming Chu
- Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
| | - Jiayi Tao
- Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
| | - Delong Kong
- Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
| | - Mengmeng Zhang
- Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
| | - Wenhua Feng
- Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
| |
Collapse
|
136
|
Abstract
This Review is devoted to the chemistry of macrocyclic peptides having heterocyclic fragments in their structure. These motifs are present in many natural products and synthetic macrocycles designed against a particular biochemical target. Thiazole and oxazole are particularly common constituents of naturally occurring macrocyclic peptide molecules. This frequency of occurrence is because the thiazole and oxazole rings originate from cysteine, serine, and threonine residues. Whereas other heteroaryl groups are found less frequently, they offer many insightful lessons that range from conformational control to receptor/ligand interactions. Many options to develop new and improved technologies to prepare natural products have appeared in recent years, and the synthetic community has been pursuing synthetic macrocycles that have no precedent in nature. This Review attempts to summarize progress in this area.
Collapse
Affiliation(s)
- Ivan V Smolyar
- Department of Chemistry , Moscow State University , Leninskije Gory , 199991 Moscow , Russia
| | - Andrei K Yudin
- Davenport Research Laboratories, Department of Chemistry , University of Toronto , 80 St. George Street , Toronto , Ontario M5S 3H6 , Canada
| | - Valentine G Nenajdenko
- Department of Chemistry , Moscow State University , Leninskije Gory , 199991 Moscow , Russia
| |
Collapse
|
137
|
Dissolving microneedle based transdermal delivery of therapeutic peptide analogues. Int J Pharm 2019; 565:9-19. [DOI: 10.1016/j.ijpharm.2019.04.075] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2018] [Revised: 04/26/2019] [Accepted: 04/29/2019] [Indexed: 12/19/2022]
|
138
|
Hirasawa S, Kitahara Y, Okamatsu Y, Fujii T, Nakayama A, Ueno S, Ijichi C, Futaki F, Nakata K, Taki M. Facile and Efficient Chemoenzymatic Semisynthesis of Fc-Fusion Compounds for Half-Life Extension of Pharmaceutical Components. Bioconjug Chem 2019; 30:2323-2331. [PMID: 31038930 DOI: 10.1021/acs.bioconjchem.9b00235] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The formation of Fc-fusions, in which biologically active molecules and the Fc fragment of antibodies are linked to each other, is one of the most efficient and successful half-life extension technologies to be developed and applied to peptide and protein pharmaceuticals thus far. Fc-fusion compounds are generally produced by recombinant methods. However, these cannot be applied to artificial middle molecules, such as peptides with non-natural amino acids, unnatural cyclic peptides, or pharmaceutical oligonucleotides. Here, we developed a simple, efficient, semisynthetic method for Fc-fusion production involving our previously developed enzymatic N-terminal extension reaction (i.e., NEXT-A reaction) and strain-promoted azide-alkyne cycloaddition, achieving quantitative conversion and high selectivity for the N-terminus of the Fc protein. An Fc-fusion compound prepared by this method showed comparable biological activity to that of the original peptide and a long-circulating plasma half-life. Thus, the proposed method is potentially applicable for the conjugation of a wide range of pharmaceutical components.
Collapse
Affiliation(s)
- Shigeo Hirasawa
- Department of Engineering Science, Graduate School of Informatics and Engineering , The University of Electro-Communications (UEC) , 1-5-1 Chofugaoka , Chofu , Tokyo 182-8585 , Japan
| | | | | | | | | | | | | | | | | | - Masumi Taki
- Department of Engineering Science, Graduate School of Informatics and Engineering , The University of Electro-Communications (UEC) , 1-5-1 Chofugaoka , Chofu , Tokyo 182-8585 , Japan
| |
Collapse
|
139
|
Huo Y, Buckton LK, Bennett JL, Smith EC, Byrne FL, Hoehn KL, Rahimi MN, McAlpine SR. Delivering bioactive cyclic peptides that target Hsp90 as prodrugs. J Enzyme Inhib Med Chem 2019; 34:728-739. [PMID: 30822267 PMCID: PMC6407599 DOI: 10.1080/14756366.2019.1580276] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The most challenging issue facing peptide drug development is producing a molecule with optimal physical properties while maintaining target binding affinity. Masking peptides with protecting groups that can be removed inside the cell, produces a cell-permeable peptide, which theoretically can maintain its biological activity. Described are series of prodrugs masked using: (a) O-alkyl, (b) N-alkyl, and (c) acetyl groups, and their binding affinity for Hsp90. Alkyl moieties increased compound permeability, Papp, from 3.3 to 5.6, however alkyls could not be removed by liver microsomes or in-vivo and their presence decreased target binding affinity (IC50 of ≥10 µM). Thus, unlike small molecules, peptide masking groups cannot be predictably removed; their removal is related to the 3-D conformation. O-acetyl groups were cleaved but are labile, increasing challenges during synthesis. Utilising acetyl groups coupled with mono-methylated amines may decrease the polarity of a peptide, while maintaining binding affinity.
Collapse
Affiliation(s)
- Yuantao Huo
- a School of Chemistry, University of New South Wales , Sydney , Australia
| | - Laura K Buckton
- a School of Chemistry, University of New South Wales , Sydney , Australia
| | - Jack L Bennett
- a School of Chemistry, University of New South Wales , Sydney , Australia
| | - Eloise C Smith
- a School of Chemistry, University of New South Wales , Sydney , Australia
| | - Frances L Byrne
- b School of Biotechnology and Biomolecular Sciences, University of New South Wales , Sydney , Australia
| | - Kyle L Hoehn
- b School of Biotechnology and Biomolecular Sciences, University of New South Wales , Sydney , Australia
| | - Marwa N Rahimi
- a School of Chemistry, University of New South Wales , Sydney , Australia
| | - Shelli R McAlpine
- a School of Chemistry, University of New South Wales , Sydney , Australia
| |
Collapse
|
140
|
Miragoli M, Ceriotti P, Iafisco M, Vacchiano M, Salvarani N, Alogna A, Carullo P, Ramirez-Rodríguez GB, Patrício T, Esposti LD, Rossi F, Ravanetti F, Pinelli S, Alinovi R, Erreni M, Rossi S, Condorelli G, Post H, Tampieri A, Catalucci D. Inhalation of peptide-loaded nanoparticles improves heart failure. Sci Transl Med 2019; 10:10/424/eaan6205. [PMID: 29343624 DOI: 10.1126/scitranslmed.aan6205] [Citation(s) in RCA: 106] [Impact Index Per Article: 21.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 08/17/2017] [Accepted: 11/29/2017] [Indexed: 12/12/2022]
Abstract
Peptides are highly selective and efficacious for the treatment of cardiovascular and other diseases. However, it is currently not possible to administer peptides for cardiac-targeting therapy via a noninvasive procedure, thus representing scientific and technological challenges. We demonstrate that inhalation of small (<50 nm in diameter) biocompatible and biodegradable calcium phosphate nanoparticles (CaPs) allows for rapid translocation of CaPs from the pulmonary tree to the bloodstream and to the myocardium, where their cargo is quickly released. Treatment of a rodent model of diabetic cardiomyopathy by inhalation of CaPs loaded with a therapeutic mimetic peptide that we previously demonstrated to improve myocardial contraction resulted in restoration of cardiac function. Translation to a porcine large animal model provides evidence that inhalation of a peptide-loaded CaP formulation is an effective method of targeted administration to the heart. Together, these results demonstrate that inhalation of biocompatible tailored peptide nanocarriers represents a pioneering approach for the pharmacological treatment of heart failure.
Collapse
Affiliation(s)
- Michele Miragoli
- Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy. .,Department of Medicine and Surgery, University of Parma, Parma 43126, Italy.,Institute of Genetics and Biomedical Research, Milan Unit, National Research Council, Milan 20138, Italy
| | - Paola Ceriotti
- Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy.,Institute of Genetics and Biomedical Research, Milan Unit, National Research Council, Milan 20138, Italy
| | - Michele Iafisco
- Institute of Science and Technology for Ceramics, National Research Council, Faenza, Ravenna 48018, Italy
| | - Marco Vacchiano
- Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy
| | - Nicolò Salvarani
- Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy.,Institute of Genetics and Biomedical Research, Milan Unit, National Research Council, Milan 20138, Italy
| | - Alessio Alogna
- Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin, Berlin 13353, Germany.,Berlin Institute of Health, Berlin 10117, Germany
| | - Pierluigi Carullo
- Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy.,Institute of Genetics and Biomedical Research, Milan Unit, National Research Council, Milan 20138, Italy
| | | | - Tatiana Patrício
- Institute of Science and Technology for Ceramics, National Research Council, Faenza, Ravenna 48018, Italy
| | - Lorenzo Degli Esposti
- Institute of Science and Technology for Ceramics, National Research Council, Faenza, Ravenna 48018, Italy
| | - Francesca Rossi
- Institute of Materials for Electronics and Magnetism, National Research Council, Parma 43126, Italy
| | | | - Silvana Pinelli
- Department of Medicine and Surgery, University of Parma, Parma 43126, Italy
| | - Rossella Alinovi
- Department of Medicine and Surgery, University of Parma, Parma 43126, Italy
| | - Marco Erreni
- Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy.,Humanitas University, Rozzano, Milan 20089, Italy
| | - Stefano Rossi
- Department of Medicine and Surgery, University of Parma, Parma 43126, Italy
| | - Gianluigi Condorelli
- Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy.,Institute of Genetics and Biomedical Research, Milan Unit, National Research Council, Milan 20138, Italy.,Humanitas University, Rozzano, Milan 20089, Italy
| | - Heiner Post
- Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin, Berlin 13353, Germany.,Department of Cardiology, Contilia Heart and Vessel Centre, St. Marien-Hospital Mülheim, Mülheim 45468, Germany
| | - Anna Tampieri
- Institute of Science and Technology for Ceramics, National Research Council, Faenza, Ravenna 48018, Italy
| | - Daniele Catalucci
- Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy. .,Institute of Genetics and Biomedical Research, Milan Unit, National Research Council, Milan 20138, Italy
| |
Collapse
|
141
|
Are peptides a solution for the treatment of hyperactivated JAK3 pathways? Inflammopharmacology 2019; 27:433-452. [PMID: 30929155 DOI: 10.1007/s10787-019-00589-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Accepted: 03/18/2019] [Indexed: 01/10/2023]
Abstract
While the inactivation mutations that eliminate JAK3 function lead to the immunological disorders such as severe combined immunodeficiency, activation mutations, causing constitutive JAK3 signaling, are known to trigger various types of cancer or are responsible for autoimmune diseases, such as rheumatoid arthritis, psoriasis, or inflammatory bowel diseases. Treatment of hyperactivated JAK3 is still an obstacle, due to different sensibility of mutation types to conventional drugs and unwanted side effects, because these drugs are not absolutely specific for JAK3, thus inhibiting other members of the JAK family, too. Lack of information, in which way sole inhibition of JAK3 is necessary for elimination of the disease, calls for the development of isoform-specific JAK3 inhibitors. Beside this strategy, up to date peptides are a rising alternative as chemo- or immunotherapeutics, but still sparsely represented in drug development and clinical trials. Beyond a possible direct inhibition function, crossing the cancer cell membrane and interfering in disease-causing pathways or triggering apoptosis, peptides could be used in future as adjunct remedies to potentialize traditional therapy and preserve non-affected cells. To discuss such feasible topics, this review deals with the knowledge about the structure-function of JAK3 and the actual state-of-the-art of isoform-specific inhibitor development, as well as the function of currently approved drugs or those currently being tested in clinical trials. Furthermore, several strategies for the application of peptide-based drugs for cancer therapy and the physicochemical and structural relations to peptide efficacy are discussed, and an overview of peptide sequences, which were qualified for clinical trials, is given.
Collapse
|
142
|
Gall FM, Hohl D, Frasson D, Wermelinger T, Mittl PRE, Sievers M, Riedl R. Von der Natur inspiriertes Wirkstoffdesign: kristallographische Detektion eines selbstgenerierten Inhibitor‐Grundgerüsts. Angew Chem Int Ed Engl 2019. [DOI: 10.1002/ange.201812348] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Flavio M. Gall
- Institut für Chemie und BiotechnologieFachgruppe Organische Chemie und MedizinalchemieZHAW Zürcher Hochschule für Angewandte Wissenschaften Einsiedlerstrasse 31 8820 Wädenswil Schweiz
| | - Deborah Hohl
- Institut für Chemie und BiotechnologieFachgruppe Organische Chemie und MedizinalchemieZHAW Zürcher Hochschule für Angewandte Wissenschaften Einsiedlerstrasse 31 8820 Wädenswil Schweiz
| | - David Frasson
- Institut für Chemie und Biotechnologie, Fachgruppe MolekularbiologieZHAW Zürcher Hochschule für Angewandte Wissenschaften Einsiedlerstrasse 31 8820 Wädenswil Schweiz
| | - Tobias Wermelinger
- Institut für Chemie und Biotechnologie, Fachgruppe MolekularbiologieZHAW Zürcher Hochschule für Angewandte Wissenschaften Einsiedlerstrasse 31 8820 Wädenswil Schweiz
| | - Peer R. E. Mittl
- Biochemisches InstitutUniversität Zürich Winterthurerstrasse 190 8057 Zürich Schweiz
| | - Martin Sievers
- Institut für Chemie und Biotechnologie, Fachgruppe MolekularbiologieZHAW Zürcher Hochschule für Angewandte Wissenschaften Einsiedlerstrasse 31 8820 Wädenswil Schweiz
| | - Rainer Riedl
- Institut für Chemie und BiotechnologieFachgruppe Organische Chemie und MedizinalchemieZHAW Zürcher Hochschule für Angewandte Wissenschaften Einsiedlerstrasse 31 8820 Wädenswil Schweiz
| |
Collapse
|
143
|
Gall FM, Hohl D, Frasson D, Wermelinger T, Mittl PRE, Sievers M, Riedl R. Drug Design Inspired by Nature: Crystallographic Detection of an Auto‐Tailored Protease Inhibitor Template. Angew Chem Int Ed Engl 2019; 58:4051-4055. [DOI: 10.1002/anie.201812348] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2018] [Revised: 12/07/2018] [Indexed: 12/31/2022]
Affiliation(s)
- Flavio M. Gall
- Institute of Chemistry and BiotechnologyCenter of Organic and Medicinal ChemistryZHAW Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Deborah Hohl
- Institute of Chemistry and BiotechnologyCenter of Organic and Medicinal ChemistryZHAW Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - David Frasson
- Institute of Chemistry and BiotechnologyCenter of Molecular BiologyZHAW Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Tobias Wermelinger
- Institute of Chemistry and BiotechnologyCenter of Molecular BiologyZHAW Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Peer R. E. Mittl
- Department of BiochemistryUniversity of Zurich Winterthurerstrasse 190 8057 Zürich Switzerland
| | - Martin Sievers
- Institute of Chemistry and BiotechnologyCenter of Molecular BiologyZHAW Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Rainer Riedl
- Institute of Chemistry and BiotechnologyCenter of Organic and Medicinal ChemistryZHAW Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| |
Collapse
|
144
|
Pensa NW, Curry AS, Reddy MS, Bellis SL. The addition of a polyglutamate domain to the angiogenic QK peptide improves peptide coupling to bone graft materials leading to enhanced endothelial cell activation. PLoS One 2019; 14:e0213592. [PMID: 30856221 PMCID: PMC6411101 DOI: 10.1371/journal.pone.0213592] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Accepted: 02/25/2019] [Indexed: 12/26/2022] Open
Abstract
Vascularization of bone grafts is vital for graft integration and bone repair, however non-autologous graft sources have limited potential to induce angiogenesis. Accordingly, intensive research has focused on functionalizing non-autologous materials with angiogenic factors. In the current study we evaluated a method for coupling an angiogenic peptide to the surface of two clinically-relevant graft materials, anorganic bovine bone (ABB) and synthetic hydroxyapatite (HA). Specifically, the VEGF-derived “QK” peptide was synthesized with a heptaglutamate (E7) domain, a motif that has strong affinity for calcium phosphate graft materials. Compared with unmodified QK, a 4–6 fold enrichment was observed in the binding of E7-modified QK (E7-QK) to ABB and HA. The E7-QK peptide was then assessed for its capacity to stimulate angiogenic cell behaviors. Human umbilical vein endothelial cells (HUVECs) were treated with solutions of either QK or E7-QK, and it was found that QK and E7-QK elicited equivalent levels of cell migration, tubule formation and activation of the Akt and ERK signaling pathways. These data confirmed that the inherent bioactivity of the QK sequence was not diminished by the addition of the E7 domain. We further verified that the activity of E7-QK was retained following peptide binding to the graft surface. HA disks were coated with QK or E7-QK, and then HUVECs were seeded onto the disks. Consistent with the increased amount of E7-QK bound to HA, relative to QK, markedly greater activation of Akt and ERK 1/2 was observed in cells exposed to the E7-QK-coated disks. Taken together, these results suggest that the E7 domain can be leveraged to concentrate angiogenic peptides on graft materials, facilitating delivery of higher peptide concentrations within the graft site. The ability to endow diverse graft materials with angiogenic potential holds promise for augmenting the regenerative capacity of non-autologous bone grafts.
Collapse
Affiliation(s)
- Nicholas W. Pensa
- Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
| | - Andrew S. Curry
- Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
| | - Michael S. Reddy
- School of Dentistry, University of California, San Francisco, California, United States of America
- * E-mail: (SLB); (MSR)
| | - Susan L. Bellis
- Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
- * E-mail: (SLB); (MSR)
| |
Collapse
|
145
|
Heyl DL, Champion M, Muterspaugh R, Connolly M, Baraka A, Khazaei P, Moe B, Al-Sheemary Z, Jaber N, Guy-Evans H. Characterizing the binding of dopamine D1-D2 receptors in vitro and in temporal and frontal lobe tissue total protein. FEBS Lett 2019; 593:732-742. [PMID: 30821397 DOI: 10.1002/1873-3468.13351] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Revised: 02/15/2019] [Accepted: 02/19/2019] [Indexed: 01/11/2023]
Abstract
Dysfunction of the dopaminergic pathway is linked to numerous diseases of the nervous system. The D1-D2 receptor heteromer is known to play a role in certain neuropsychiatric disorders, such as depression. Here, we synthesized an eight amino acid residue peptide, EAARRAQE, derived from the third intracellular loop of the D2 receptor and show that the peptide binds to the D1 receptor with comparable efficiency as that of the full-length D2 receptor protein. Moreover, immunoprecipitation studies show the existence of a heteromeric complex formed both in vitro and in total protein derived from temporal and frontal lobe tissue from normal and depressed subjects. The efficiency of the peptide to block the D1-D2 heteromeric complex was comparable in all the samples tested.
Collapse
Affiliation(s)
- Deborah L Heyl
- Chemistry Department, Eastern Michigan University, Ypsilanti, MI, USA
| | - Margaret Champion
- Chemistry Department, Eastern Michigan University, Ypsilanti, MI, USA
| | | | - Megan Connolly
- Chemistry Department, Eastern Michigan University, Ypsilanti, MI, USA
| | - Adam Baraka
- Chemistry Department, Eastern Michigan University, Ypsilanti, MI, USA
| | - Pouya Khazaei
- Chemistry Department, Eastern Michigan University, Ypsilanti, MI, USA
| | - Briana Moe
- Chemistry Department, Eastern Michigan University, Ypsilanti, MI, USA
| | | | - Nael Jaber
- Chemistry Department, Eastern Michigan University, Ypsilanti, MI, USA
| | - Hedeel Guy-Evans
- Chemistry Department, Eastern Michigan University, Ypsilanti, MI, USA
| |
Collapse
|
146
|
Aitbakieva VR, Ahmad R, Singh S, Domashevskiy AV. Inhibition of ricin A-chain (RTA) catalytic activity by a viral genome-linked protein (VPg). BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS 2019; 1867:645-653. [PMID: 30822539 DOI: 10.1016/j.bbapap.2019.02.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/15/2018] [Revised: 02/04/2019] [Accepted: 02/13/2019] [Indexed: 12/01/2022]
Abstract
Ricin is a plant derived protein toxin produced by the castor bean plant (Ricinus communis). The Centers for Disease Control (CDC) classifies ricin as a Category B biological agent. Currently, there is neither an effective vaccine that can be used to protect against ricin exposure nor a therapeutic to reverse the effects once exposed. Here we quantitatively characterize interactions between catalytic ricin A-chain (RTA) and a viral genome-linked protein (VPg) from turnip mosaic virus (TuMV). VPg and its N-terminal truncated variant, VPg1-110, bind to RTA and abolish ricin's catalytic depurination of 28S rRNA in vitro and in a cell-free rabbit reticulocyte translational system. RTA and VPg bind in a 1 to 1 stoichiometric ratio, and their binding affinity increases ten-fold as temperature elevates (5 °C to 37 °C). RTA-VPg binary complex formation is enthalpically driven and favored by entropy, resulting in an overall favorable energy, ΔG = -136.8 kJ/mol. Molecular modeling supports our experimental observations and predicts a major contribution of electrostatic interactions, suggesting an allosteric mechanism of downregulation of RTA activity through conformational changes in RTA structure, and/or disruption of binding with the ribosomal stalk. Fluorescence anisotropy studies show that heat affects the rate constant and the activation energy for the RTA-VPg complex, Ea = -62.1 kJ/mol. The thermodynamic and kinetic findings presented here are an initial lead study with promising results and provides a rational approach for synthesis of therapeutic peptides that successfully eliminate toxicity of ricin, and other cytotoxic RIPs.
Collapse
Affiliation(s)
- Valentina R Aitbakieva
- Department of Sciences, John Jay College of Criminal Justice, the City University of New York, New York 10019, NY, United States of America
| | - Rahimah Ahmad
- Department of Biology, Brooklyn College, The City University of New York, Brooklyn, New York 11210, United States of America
| | - Shaneen Singh
- Department of Biology, Brooklyn College, The City University of New York, Brooklyn, New York 11210, United States of America
| | - Artem V Domashevskiy
- Department of Sciences, John Jay College of Criminal Justice, the City University of New York, New York 10019, NY, United States of America.
| |
Collapse
|
147
|
Cauchon NS, Oghamian S, Hassanpour S, Abernathy M. Innovation in Chemistry, Manufacturing, and Controls-A Regulatory Perspective From Industry. J Pharm Sci 2019; 108:2207-2237. [PMID: 30794794 DOI: 10.1016/j.xphs.2019.02.007] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Revised: 02/07/2019] [Accepted: 02/14/2019] [Indexed: 12/31/2022]
Abstract
This review describes the landscape of novel modalities such as cell and gene therapies, viruses, other novel biologics, oligomers, and emerging technologies, including modern analytics. We summarize the regulatory history and recent landmark developments in some major markets and examine specific chemistry, manufacturing, and controls (CMC) challenges, including suggestions for exploration of potential science-based approaches in support of regulatory strategy development from an industry perspective. In addition, we evaluate the economic factors contributing to patient access to innovation and discuss the impact of regulation. There is a desperate need for a consistent form of regulation where global approaches to regulatory strategies can be harmonized, and specific CMC challenges can be dealt with using the appropriate science and risk-based tools. Although these tools are well described in current guidance documents, the specifics of applicability to complex novel modalities can still result in differing regulatory advice and outcomes. The future goals for efficiently regulating innovative modalities and technologies could be aided by more regulatory harmonization, regulatory education, and industry cooperation through consortia, enabling industry to supply key information to regulators in a transparent yet well-defined manner, and utilizing mutually understood risk-benefit analyses to produce drugs with appropriate safety, efficacy, and quality characteristics.
Collapse
Affiliation(s)
- Nina S Cauchon
- Department of Global Regulatory Affairs and Safety-CMC, Amgen Inc, Thousand Oaks, California 91320.
| | - Shirley Oghamian
- Department of Global Regulatory Affairs and Safety-CMC, Amgen Inc, Thousand Oaks, California 91320
| | - Soraya Hassanpour
- Department of Global Regulatory Affairs and Safety-CMC, Amgen Inc, Thousand Oaks, California 91320; Rutgers Pharmaceutical Industry Fellowship Program, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey 08854
| | - Michael Abernathy
- Department of Global Regulatory Affairs and Safety-CMC, Amgen Inc, Thousand Oaks, California 91320
| |
Collapse
|
148
|
Kaplaneris N, Rogge T, Yin R, Wang H, Sirvinskaite G, Ackermann L. Late-Stage Diversification through Manganese-Catalyzed C−H Activation: Access to Acyclic, Hybrid, and Stapled Peptides. Angew Chem Int Ed Engl 2019. [DOI: 10.1002/ange.201812705] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Nikolaos Kaplaneris
- Institut für Organische und Biomolekulare Chemie; Georg-August-Universität Göttingen; Tammanstraße 2 37077 Göttingen Germany
| | - Torben Rogge
- Institut für Organische und Biomolekulare Chemie; Georg-August-Universität Göttingen; Tammanstraße 2 37077 Göttingen Germany
| | - Rongxin Yin
- Institut für Organische und Biomolekulare Chemie; Georg-August-Universität Göttingen; Tammanstraße 2 37077 Göttingen Germany
| | - Hui Wang
- Institut für Organische und Biomolekulare Chemie; Georg-August-Universität Göttingen; Tammanstraße 2 37077 Göttingen Germany
| | - Giedre Sirvinskaite
- Institut für Organische und Biomolekulare Chemie; Georg-August-Universität Göttingen; Tammanstraße 2 37077 Göttingen Germany
| | - Lutz Ackermann
- Institut für Organische und Biomolekulare Chemie; Georg-August-Universität Göttingen; Tammanstraße 2 37077 Göttingen Germany
| |
Collapse
|
149
|
Kaplaneris N, Rogge T, Yin R, Wang H, Sirvinskaite G, Ackermann L. Late-Stage Diversification through Manganese-Catalyzed C-H Activation: Access to Acyclic, Hybrid, and Stapled Peptides. Angew Chem Int Ed Engl 2019; 58:3476-3480. [PMID: 30565829 DOI: 10.1002/anie.201812705] [Citation(s) in RCA: 63] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Indexed: 12/16/2022]
Abstract
Bioorthogonal C-H allylation with ample scope was accomplished through a versatile manganese(I)-catalyzed C-H activation for the late-stage diversification of structurally complex peptides. The unique robustness of the manganese(I) catalysis manifold was reflected by full tolerance of sensitive functional groups, such as iodides, esters, amides, and OH-free hydroxy groups, thereby setting the stage for the racemization-free synthesis of C-H fused peptide hybrids featuring steroids, drug molecules, natural products, nucleobases, and saccharides.
Collapse
Affiliation(s)
- Nikolaos Kaplaneris
- Institut für Organische und Biomolekulare Chemie, Georg-August-Universität Göttingen, Tammanstraße 2, 37077, Göttingen, Germany
| | - Torben Rogge
- Institut für Organische und Biomolekulare Chemie, Georg-August-Universität Göttingen, Tammanstraße 2, 37077, Göttingen, Germany
| | - Rongxin Yin
- Institut für Organische und Biomolekulare Chemie, Georg-August-Universität Göttingen, Tammanstraße 2, 37077, Göttingen, Germany
| | - Hui Wang
- Institut für Organische und Biomolekulare Chemie, Georg-August-Universität Göttingen, Tammanstraße 2, 37077, Göttingen, Germany
| | - Giedre Sirvinskaite
- Institut für Organische und Biomolekulare Chemie, Georg-August-Universität Göttingen, Tammanstraße 2, 37077, Göttingen, Germany
| | - Lutz Ackermann
- Institut für Organische und Biomolekulare Chemie, Georg-August-Universität Göttingen, Tammanstraße 2, 37077, Göttingen, Germany
| |
Collapse
|
150
|
Lorion MM, Kaplaneris N, Son J, Kuniyil R, Ackermann L. Late‐Stage Peptide Diversification through Cobalt‐Catalyzed C−H Activation: Sequential Multicatalysis for Stapled Peptides. Angew Chem Int Ed Engl 2019. [DOI: 10.1002/ange.201811668] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Mélanie M. Lorion
- Institut für Organische und Biomolekulare ChemieGeorg-August-Universität Tammanstr. 2 37077 Göttingen Germany
| | - Nikolaos Kaplaneris
- Institut für Organische und Biomolekulare ChemieGeorg-August-Universität Tammanstr. 2 37077 Göttingen Germany
| | - Jongwoo Son
- Institut für Organische und Biomolekulare ChemieGeorg-August-Universität Tammanstr. 2 37077 Göttingen Germany
| | - Rositha Kuniyil
- Institut für Organische und Biomolekulare ChemieGeorg-August-Universität Tammanstr. 2 37077 Göttingen Germany
| | - Lutz Ackermann
- Institut für Organische und Biomolekulare ChemieGeorg-August-Universität Tammanstr. 2 37077 Göttingen Germany
- DZHK (German Center for Cardiovascular Research) Germany
| |
Collapse
|